ATE461941T1 - Antikörper gegen alzheimer spezifische tau proteine mit abnormaler konformation - Google Patents

Antikörper gegen alzheimer spezifische tau proteine mit abnormaler konformation

Info

Publication number
ATE461941T1
ATE461941T1 AT02703586T AT02703586T ATE461941T1 AT E461941 T1 ATE461941 T1 AT E461941T1 AT 02703586 T AT02703586 T AT 02703586T AT 02703586 T AT02703586 T AT 02703586T AT E461941 T1 ATE461941 T1 AT E461941T1
Authority
AT
Austria
Prior art keywords
antibodies against
tau proteins
against alzheimer
specific tau
abnormal conformation
Prior art date
Application number
AT02703586T
Other languages
English (en)
Inventor
Michal Novak
Original Assignee
Axon Neuroscience
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axon Neuroscience filed Critical Axon Neuroscience
Application granted granted Critical
Publication of ATE461941T1 publication Critical patent/ATE461941T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Psychology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT02703586T 2001-02-02 2002-01-29 Antikörper gegen alzheimer spezifische tau proteine mit abnormaler konformation ATE461941T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AT0017501A AT500379B8 (de) 2001-02-02 2001-02-02 Tau-proteine
PCT/EP2002/000897 WO2002062851A1 (en) 2001-02-02 2002-01-29 Conformationally abnormal forms of tau proteins and specific antibodies thereto

Publications (1)

Publication Number Publication Date
ATE461941T1 true ATE461941T1 (de) 2010-04-15

Family

ID=3658236

Family Applications (2)

Application Number Title Priority Date Filing Date
AT0017501A AT500379B8 (de) 2001-02-02 2001-02-02 Tau-proteine
AT02703586T ATE461941T1 (de) 2001-02-02 2002-01-29 Antikörper gegen alzheimer spezifische tau proteine mit abnormaler konformation

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT0017501A AT500379B8 (de) 2001-02-02 2001-02-02 Tau-proteine

Country Status (12)

Country Link
US (2) US7446180B2 (de)
EP (1) EP1355949B1 (de)
JP (1) JP4163955B2 (de)
CN (2) CN101307107A (de)
AT (2) AT500379B8 (de)
AU (1) AU2002237296A1 (de)
CA (1) CA2437453C (de)
DE (1) DE60235746D1 (de)
DK (1) DK1355949T3 (de)
ES (1) ES2339427T3 (de)
RU (1) RU2299889C2 (de)
WO (1) WO2002062851A1 (de)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT500379B8 (de) 2001-02-02 2009-08-15 Axon Neuroscience Tau-proteine
JP4414332B2 (ja) * 2002-07-12 2010-02-10 アクソン・ニューロサイエンス・フォルシュングス−ウント・エントヴィックルングス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング アルツハイマーｔａｕタンパク質を発現するトランスジェニック動物
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
BRPI0619249A2 (pt) 2005-11-30 2011-09-20 Abbott Lab anticorpos anti-globulÈmeros-aß, frações que se ligam a antìgeno destes, hibridomas correspondentes, ácidos nucléicos, vetores, células hospedeiras, métodos de produzir os ditos anticorpos, composições compreendendo os ditos anticorpos, usos dos ditos anticorpos e métodos de usar os ditos anticorpos
PT1976877E (pt) 2005-11-30 2014-04-29 Abbvie Inc Anticorpos monoclonais contra proteína beta-amilóide e suas utilizações
ES2321996B1 (es) * 2006-01-26 2010-03-05 Consejo Superior Investig. Cientificas Uso de compuestos que se unen al dominio de union a microtubulos de tau en la elaboracion de composiciones farmaceuticas, dichas composiciones farmaceuticas y su aplicacion en el tratamiento de tauopatias.
US8012936B2 (en) 2006-03-29 2011-09-06 New York University Tau fragments for immunotherapy
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
EP2124952A2 (de) 2007-02-27 2009-12-02 Abbott GmbH & Co. KG Verfahren zur behandlung von amyloidosen
WO2009143556A1 (en) * 2008-05-30 2009-12-03 The University Of Sydney TREATMENTS FOR EXCITOTOXICITY AND Aß-MEDIATED TOXICITY AND AGE-ASSOCIATED NEURONAL DYSFUNCTION
CA3239368A1 (en) 2009-06-10 2010-12-16 New York University Immunological targeting of pathological tau proteins
US8609097B2 (en) * 2009-06-10 2013-12-17 Hoffmann-La Roche Inc. Use of an anti-Tau pS422 antibody for the treatment of brain diseases
US9125846B2 (en) 2010-10-15 2015-09-08 The Board Of Regents Of The University Of Texas System Antibodies that bind amyloid oligomers
AU2010286501B2 (en) * 2009-08-28 2015-06-11 The Board Of Regents Of The University Of Texas System Antibodies that bind Tau oligomers
US10266585B2 (en) 2009-08-28 2019-04-23 The Board Of Regents Of The Univerity Of Texas System Methods of treating brain injury
EP2558494B1 (de) 2010-04-15 2018-05-23 AbbVie Inc. Amyloid-beta-bindende proteine
ITRM20100320A1 (it) * 2010-06-11 2011-12-11 Consiglio Nazionale Ricerche Metodo per la diagnostica e il trattamento delle taupatie
CN105348387B (zh) 2010-08-14 2020-08-25 Abbvie 公司 β淀粉样蛋白结合蛋白
SG189174A1 (en) 2010-10-11 2013-05-31 Biogen Idec Internat Neuroscience Gmbh Human anti-tau antibodies
US8703137B2 (en) 2011-01-31 2014-04-22 Intellect Neurosciences Inc. Treatment of tauopathies
EP2709728B1 (de) * 2011-05-20 2019-01-23 Oligomerix, Inc. Tau-protease-anwendungsverfahren
US9518101B2 (en) * 2011-09-19 2016-12-13 Axon Neuroscience Se Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease
ES2600915T3 (es) 2011-10-07 2017-02-13 Ac Immune S.A. Anticuerpos fosfoespecíficos que reconocen Tau
JP6345655B2 (ja) 2012-07-03 2018-06-20 ワシントン・ユニバーシティＷａｓｈｉｎｇｔｏｎ Ｕｎｉｖｅｒｓｉｔｙ タウに対する抗体
DK2885010T3 (da) 2012-08-16 2020-02-03 Ipierian Inc Fremgangsmåder til behandling med tauopati
US9200068B2 (en) * 2012-12-18 2015-12-01 Regents Of The University Of Minnesota Compositions and methods related to tauopathy
HRP20201422T1 (hr) 2012-12-21 2021-02-19 Biogen Ma Inc. Ljudska anti-tau antitijela
US8980270B2 (en) 2013-01-18 2015-03-17 Ipierian, Inc. Methods of treating a tauopathy
MX375354B (es) 2013-03-13 2025-03-06 Prothena Biosciences Ltd Anticuerpos que se unen a tau y usos de los mismos.
BR112015023262B8 (pt) * 2013-03-15 2024-02-06 Ac Immune Sa Anticorpo isolado, imunoconjugado, formulação farmacêutica e usos do anticorpo
SI3083680T1 (sl) 2013-12-20 2020-06-30 F. Hoffmann-La Roche Ag Humanizirana protitelesa proti beljakovini Tau(pS422) in postopki uporabe
JP2017512751A (ja) 2014-02-14 2017-05-25 アイピエリアン，インコーポレイティド タウペプチド、抗タウ抗体、およびそれらの使用方法
AR100978A1 (es) 2014-06-26 2016-11-16 Hoffmann La Roche LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS
TW202136296A (zh) * 2014-06-27 2021-10-01 美商Ｃ２Ｎ醫療診斷有限責任公司 人類化抗-tau抗體
JP6913018B2 (ja) 2014-07-08 2021-08-04 ニューヨーク・ユニバーシティ タウイメージングリガンド、ならびにタウ異常症の診断および治療におけるそれらの使用
JO3576B1 (ar) 2015-02-26 2020-07-05 Lilly Co Eli أجسام مضادة لـ tau واستخداماتها
UA126272C2 (uk) 2015-06-05 2022-09-14 Дженентек, Інк. Антитіло проти тау-білка та спосіб його застосування
CN107810196B (zh) 2015-06-24 2021-11-05 豪夫迈·罗氏有限公司 人源化的抗-Tau(pS422)抗体和使用方法
EA037092B1 (ru) * 2015-07-06 2021-02-04 Юсб Биофарма Срл Тау-связывающие антитела
CN108135986B (zh) 2015-08-13 2022-07-29 纽约大学 对于Tau的截短的Asp421表位特异性的基于抗体的分子和它们在诊断和治疗Tau疾病中的用途
CA3022673A1 (en) 2016-05-02 2017-11-09 Prothena Biosciences Limited Tau immunotherapy
CA3022515A1 (en) 2016-05-02 2017-11-09 Prothena Biosciences Limited Antibodies recognizing tau
KR102551971B1 (ko) * 2016-07-12 2023-07-07 하. 룬드벡 아크티에셀스카브 과인산화된 타우에 특이적인 항체 및 이의 사용 방법
EP3496750A2 (de) 2016-08-09 2019-06-19 Eli Lilly and Company Kombinationstherapie
KR20240035636A (ko) 2016-12-07 2024-03-15 제넨테크, 인크. 항-타우 항체 및 이의 이용 방법
AR110321A1 (es) 2016-12-07 2019-03-20 Genentech Inc Anticuerpos antitau y métodos de uso
KR102784294B1 (ko) 2017-05-02 2025-03-19 프로테나 바이오사이언시즈 리미티드 타우 인식 항체
EP3658172A4 (de) 2017-07-25 2021-05-05 TrueBinding, Inc. Behandlung von krebs durch blockierung der interaktion von tim-3 und seinem liganden
CN107686839B (zh) * 2017-09-25 2020-12-04 安徽朵能生物科技有限公司 微管结合蛋白cript、其治疗性突变体及其应用
CN112543648A (zh) 2018-07-31 2021-03-23 伊莱利利公司 组合疗法
CN113711036B (zh) 2019-01-30 2025-03-18 真和制药有限公司 抗gal3抗体及其用途
CN119371527A (zh) 2019-03-03 2025-01-28 普罗塞纳生物科学有限公司 识别tau的抗体
US11845931B2 (en) 2019-03-18 2023-12-19 Regeneron Pharmaceuticals, Inc. CRISPR/Cas screening platform to identify genetic modifiers of tau seeding or aggregation
CA3135170A1 (en) 2019-04-05 2020-10-08 Tauc3 Biologics Limited Anti-tauc3 antibodies and uses thereof
GB2585252A (en) 2019-07-05 2021-01-06 Gen2 Neuroscience Ltd Tau epitope and binding molecules
CN116157151A (zh) 2020-05-26 2023-05-23 真和制药有限公司 通过阻断半乳凝素-3治疗炎性疾病的方法
WO2022144406A1 (en) 2020-12-29 2022-07-07 Neurimmune Ag Human anti-tau antibodies

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5733734A (en) * 1991-08-14 1998-03-31 The Trustees Of The University Of Pennsylvania Method of screening for Alzheimer's disease or disease associated with the accumulation of paired helical filaments
JPH06239899A (ja) 1993-02-12 1994-08-30 Teijin Ltd ヒトタウ蛋白に対する抗体、並びに該抗体を利用する体液中のヒトタウ蛋白の測定方法
AT500379B8 (de) 2001-02-02 2009-08-15 Axon Neuroscience Tau-proteine
US20020164657A1 (en) * 2001-02-23 2002-11-07 Sharma Satish K. Assays for assessing A beta-Tau aggregation

Also Published As

Publication number Publication date
DE60235746D1 (de) 2010-05-06
AT500379A2 (de) 2005-12-15
JP4163955B2 (ja) 2008-10-08
JP2004532817A (ja) 2004-10-28
CN101307107A (zh) 2008-11-19
CA2437453A1 (en) 2002-08-15
CA2437453C (en) 2013-06-11
AU2002237296A1 (en) 2002-08-19
WO2002062851A8 (en) 2002-09-12
US20040082763A1 (en) 2004-04-29
AT500379B8 (de) 2009-08-15
CN100503638C (zh) 2009-06-24
RU2299889C2 (ru) 2007-05-27
AT500379B1 (de) 2009-07-15
DK1355949T3 (da) 2010-05-25
WO2002062851A1 (en) 2002-08-15
RU2003126594A (ru) 2005-03-10
AT500379A3 (de) 2009-02-15
US20090123936A1 (en) 2009-05-14
EP1355949A1 (de) 2003-10-29
ES2339427T3 (es) 2010-05-20
CN1492879A (zh) 2004-04-28
EP1355949B1 (de) 2010-03-24
US7446180B2 (en) 2008-11-04

Similar Documents

Publication Publication Date Title
DE60235746D1 (de) Antikörper gegen Alzheimer spezifische tau Proteine mit abnormaler Konformation
EA200700083A1 (ru) Антитела, направленные против бета-амилоидного пептида, и способы их применения
EA200101250A1 (ru) Предупреждение и терапия амилоидогенного заболевания
EP3569610A3 (de) Moleküle mit verlängerter halbwertzeit, zusammensetzungen und verwendungen dafür
EP2267032A3 (de) Verfahren zur Verabreichung therapeutischer Polypeptide und Polypeptide dafür
ATE406383T1 (de) Verkürzte tau proteine
DE602004011770D1 (de) Fusionsproteine
DK1368060T3 (da) HMGB1-proteininhibitorer og/eller antagonister til behandlingen af vaskulære sygdomme
WO2001075454A3 (en) Diagnosis and treatment of alzheimer's disease
ATE510851T1 (de) Auf peptiden basierende immunisierungstherapie zur behandlung von atherosklerose
ATE376559T1 (de) Methoden der verhinderung und behandlung der alzheimer'schen krankheit
TNSN07401A1 (fr) Anticorps diriges contre le peptide amyloide-beta, et methodes pour leurs utilisations
WO2005018424A3 (en) Antibodies specific for fibrillar amyloid and a procedure to detect fibrillar amyloid deposits
GB0117326D0 (en) Napthoquinone-type inhibitors of protein aggregation
DK2172208T3 (da) Små peptider til behandling af alzheimers sygdom og andre beta-amyloidprotein- fibrillogeneseforstyrrelser
WO2005108999A3 (en) Diagnostic and therapeutic use of kcnj6 for alzheimer’s disease
WO2005012330A3 (en) AMYLOID β-PEPTIDE AND METHODS OF USE
ATE530667T1 (de) Kcnn3 als diagnostisches und therapeutisches target für alzheimer-krankheit
DE602006019582D1 (de) Adarb2 proteine als diagnostische und therapeutische targets für neurodegenerative erkrankungen
ATE396203T1 (de) Auf peptiden basierende immunisierungstherapie zur behandlung von atheriosclerose
ATE534751T1 (de) Verwendung von prkx zur diagnose und therapie von alzheimer krankheit
ATE458834T1 (de) Diagnostische und therapeutische verwendung des mal2-gens und proteins bei neurodegenerativen krankheiten
ATE365175T1 (de) Diagnostische und therapeutische verwendung von humanen maguinproteinen und nukleinsäuren bei neurodegenerativen krankheiten
ATE316657T1 (de) Diagnostische und therapeutische verwendung des caps
WO2002046769A3 (en) A monoclonal antibody-based diagnostic assay for gamma fibrinogen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1355949

Country of ref document: EP